← Russell 3000 cross-section

ALT Altimmune, Inc.

Trailing twelve months to 2025-12-31 · as filed 2026-03-06, not restated
Healthcare

Scale

Market cap
$618m
Revenue TTM
$0m
Net income TTM
$-88m
Free cash flow
Composite score
Sector rank
#2294

Valuation

P / E
EV / EBITDA
EV / sales
9,229.9
FCF yield
Earnings yield vs 10-yr
-19.00pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-214,861.0%
EBITDA margin
-230,187.8%
ROE
-39.2%
ROIC
Revenue growth
105.0%

Insider activity, last 90 days

Net open-market
$0.04m
Buyers
1
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

For instance, Nasdaq requires that we obtain stockholder approval of any transaction involving the sale, issuance or potential issuance by us of our common stock (or securities convertible into our common stock) at a price less than the greater of book or market value, which (together with sales by our officers, directors and principal stockholders) equals 20% or more of our then outstanding common stock, unless the transaction is considered a “public offering” by Nasdaq. …Altimmune, Inc., 10-K, period ended 2025-12-31, filed 2026-03-06

Read the full passage →